Randomized Phase III controlled trials of therapy in malignant glioma: where are we after 40 years?
about
Interactions among mitochondrial proteins altered in glioblastoma.Toward 3D biomimetic models to understand the behavior of glioblastoma multiforme cellsThe proteomic response in glioblastoma in young patientsPrognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region.Autologous antibody to src-homology 3-domain GRB2-like 1 specifically increases in the sera of patients with low-grade gliomas.Overcoming the challenges in the effective delivery of chemotherapies to CNS solid tumors.Cell cycle progression in glioblastoma cells is unaffected by pathophysiological levels of hypoxiaExtent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapyThe sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review.A systematic review and meta-analysis of gene therapy in animal models of cerebral glioma: why did promise not translate to human therapy?Inhibition of HDAC increases the senescence induced by natural polyphenols in glioma cells.Trends in classification, referral and treatment and the effect on outcome of patients with glioma: a 20 year cohort.Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma.Assessment of physiological parameters within glioblastomas in awake patients: a prospective clinical study.
P2860
Q33722409-E7EBA2E7-78C3-49D9-979A-DECC10F91112Q34025911-DFB62927-A561-4079-B727-5C313153D0F4Q34030167-F2605F89-A792-4784-A1AD-781E290E9809Q34168829-A208833E-0FD9-40F8-B96F-633A7D0AD855Q34439167-0E318969-A643-45CE-B3B9-2FA18F1BCCCEQ35602796-C3D9FA3F-B1BC-436A-8B83-E372287A3B74Q36663479-F955CB96-CBEC-441F-BCA7-322E5AA2B852Q37269674-C9ADCB53-B619-4A90-BC99-C59CF96EDFE9Q37846215-53A47690-E6EC-4DB3-92C3-1C0611A06BF0Q38964404-9D6EA15B-B673-4AFB-9AE5-EB7EFBEAE19EQ38970906-D250E504-56B6-435D-ABC7-C4119D99F699Q43491341-5A3F861B-0711-415D-AE79-17C0B9893FF2Q47655431-4CA7B4AB-15D7-4A14-81C7-99F4D46BA8F9Q55463922-D54F0539-82D1-4FCD-80D4-4B1A6D249C5A
P2860
Randomized Phase III controlled trials of therapy in malignant glioma: where are we after 40 years?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Randomized Phase III controlle ...... : where are we after 40 years?
@en
Randomized Phase III controlle ...... : where are we after 40 years?
@nl
type
label
Randomized Phase III controlle ...... : where are we after 40 years?
@en
Randomized Phase III controlle ...... : where are we after 40 years?
@nl
prefLabel
Randomized Phase III controlle ...... : where are we after 40 years?
@en
Randomized Phase III controlle ...... : where are we after 40 years?
@nl
P2093
P2860
P1476
Randomized Phase III controlle ...... : where are we after 40 years?
@en
P2093
P2860
P304
P356
10.1080/02688690701885603
P577
2008-06-01T00:00:00Z